At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial.
At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial.
The details of the REALISE study have been published in ClinicalTrials.gov and the Pan African Clinical Trial Registry. These details will soon be shared with the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries where patient recruitment and treatment administration will take place. The publication is an important milestone
The details of the REALISE study have been published in ClinicalTrials.gov and the Pan African Clinical Trial Registry. These details will soon be shared with the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries where patient recruitment and treatment administration will take place. The publication is an important milestone for this EDCTP funded project.
The design of this clinical trial was lead by the teams at ISGlobal and Liconsa, with support from GHS (Ghana Health Service) and KEMRI (Kenya Medical Research Institute) and other partners in our Consortium.
The design of this clinical trial was lead by the teams at ISGlobal and Liconsa, with support from GHS (Ghana Health Service) and KEMRI (Kenya Medical Research Institute) and other partners in our Consortium.
Borja Robert
10 months ago